TY - JOUR
T1 - Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies
T2 - Identification of drugs that exacerbate tachycardia and potential mechanisms
AU - Rinkenberger, Robert L.
AU - Prystowsky, Eric N.
AU - Jackman, Warren M.
AU - Naccarelli, Gerald V.
AU - Heger, James J.
AU - Zipes, Douglas P.
N1 - Funding Information:
From the Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, and the Veterans Administration Hospital. Supported in part by the Herman C. Krannert Fund, hy Grants HL-06306 and HL-07182 and from the National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, MD, and by the American Heart Association, Indiana Afiliate, Inc. Received for publication Sept. 23, 1981; accepted Sept. 26, 1981. Reprint requests: Eric N. Pry&why, M.D., Indiana University School of Medicine, 1100 West Michigan St., Indianapolis, IN 46223.
PY - 1982/2
Y1 - 1982/2
N2 - Eleven of 83 patients who had ventricular tachycardia (VT) and underwent serial electrophysiologic study (EPS) had a more severe VT induced while receiving a particular antiarrhythmic drug as compared to control study. For all patients only nonsustained VT was initiated during control study, while sustained VT occurred during drug testing with disopyramide (2 patients), quinidine (2 patients), amiodarone (4 patients), and encainide (7 patients), although spontaneous arrhythmias appeared well-controlled prior to repeat testing. Pacing techniques used to induce sustained VT were the same as those used in the control study in eight patients and "less aggressive" in three patients. Almost all episodes of sustained VT resulted in substantial hypotension, especially in patients who were taking encainide. Drugs associated with sustained VT increased the median tachycardia cycle length by 112 msec (p < 0.005) but increased the median ventricular effective refractory period by only 30 msec (p < 0.02). Assuming re-entry was responsible for VT, we postulate that drugs facilitated initiation of sustained VT by prolonging activation time but only minimally increasing refractoriness of the tachycardia circuit.
AB - Eleven of 83 patients who had ventricular tachycardia (VT) and underwent serial electrophysiologic study (EPS) had a more severe VT induced while receiving a particular antiarrhythmic drug as compared to control study. For all patients only nonsustained VT was initiated during control study, while sustained VT occurred during drug testing with disopyramide (2 patients), quinidine (2 patients), amiodarone (4 patients), and encainide (7 patients), although spontaneous arrhythmias appeared well-controlled prior to repeat testing. Pacing techniques used to induce sustained VT were the same as those used in the control study in eight patients and "less aggressive" in three patients. Almost all episodes of sustained VT resulted in substantial hypotension, especially in patients who were taking encainide. Drugs associated with sustained VT increased the median tachycardia cycle length by 112 msec (p < 0.005) but increased the median ventricular effective refractory period by only 30 msec (p < 0.02). Assuming re-entry was responsible for VT, we postulate that drugs facilitated initiation of sustained VT by prolonging activation time but only minimally increasing refractoriness of the tachycardia circuit.
UR - http://www.scopus.com/inward/record.url?scp=0020076154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020076154&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(82)90490-2
DO - 10.1016/0002-8703(82)90490-2
M3 - Article
C2 - 6798855
AN - SCOPUS:0020076154
SN - 0002-8703
VL - 103
SP - 177
EP - 184
JO - American Heart Journal
JF - American Heart Journal
IS - 2
ER -